Kieuhoa T Vo1, Steven G DuBois2, John Neuhaus3, Steve E Braunstein4, Brent R Weil5, Arlene Naranjo6, Sabine Irtan7, Julia Balaguer8, Katherine K Matthay1. 1. UCSF Benioff Children's Hospital and Departments of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California, USA. 2. Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA. 3. Epidemiology and Biostatistics, University of California, San Francisco School of Medicine, San Francisco, California, USA. 4. Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, California, USA. 5. Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 6. Department of Biostatistics, University of Florida, Children's Oncology Group Statistics and Data Center, Gainesville, Florida, USA. 7. Department of Pediatric Surgery, Hôpital d'enfants Armand-Trousseau, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France. 8. Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Abstract
PURPOSE: We sought to analyze biologic, clinical, and prognostic differences according to pattern of failure at the time of first relapse in neuroblastoma. PATIENTS AND METHODS: Children <21 years diagnosed with neuroblastoma between 1989 and 2017 with known site of first relapse (isolated local vs. distant only vs. combined local and distant sites) were identified from the International Neuroblastoma Risk Group (INRG) database. Data were compared between sites of relapse according to clinical features, biologic features, initial treatment, time to first relapse, and overall survival (OS) from time of first relapse. RESULTS: Pattern of first relapse among 1833 children was 19% isolated local; 65% distant only; and 16% combined sites. All evaluated clinical and biologic variables with exception of tumor diagnosis differed statistically by relapse pattern, with patients with isolated local failure having more favorable prognostic features. Patients with stage 3 disease were more likely to have isolated local failure compared to all other stages (49% vs. 16%; p < .001). OS significantly differed by relapse pattern (5-year OS ± SE): isolated local: 64% ± 3%; distant only: 23% ± 2%; and combined: 26% ± 4% (p < .001). After controlling for age, stage, and MYCN status, patients with isolated local failure (adjusted hazard ratio [HR] = 0.46; 95% confidence interval [CI]: 0.33-0.62; p < .001) and distant-only failure (adjusted HR = 0.57; 95% CI: 0.45-0.71; p < .001) remained at decreased risk for death as compared to patients with combined failure. CONCLUSION: Patients with distant-only and combined failures have a higher proportion of unfavorable clinical and biological features, and a lower survival than those with isolated local relapse.
PURPOSE: We sought to analyze biologic, clinical, and prognostic differences according to pattern of failure at the time of first relapse in neuroblastoma. PATIENTS AND METHODS: Children <21 years diagnosed with neuroblastoma between 1989 and 2017 with known site of first relapse (isolated local vs. distant only vs. combined local and distant sites) were identified from the International Neuroblastoma Risk Group (INRG) database. Data were compared between sites of relapse according to clinical features, biologic features, initial treatment, time to first relapse, and overall survival (OS) from time of first relapse. RESULTS: Pattern of first relapse among 1833 children was 19% isolated local; 65% distant only; and 16% combined sites. All evaluated clinical and biologic variables with exception of tumor diagnosis differed statistically by relapse pattern, with patients with isolated local failure having more favorable prognostic features. Patients with stage 3 disease were more likely to have isolated local failure compared to all other stages (49% vs. 16%; p < .001). OS significantly differed by relapse pattern (5-year OS ± SE): isolated local: 64% ± 3%; distant only: 23% ± 2%; and combined: 26% ± 4% (p < .001). After controlling for age, stage, and MYCN status, patients with isolated local failure (adjusted hazard ratio [HR] = 0.46; 95% confidence interval [CI]: 0.33-0.62; p < .001) and distant-only failure (adjusted HR = 0.57; 95% CI: 0.45-0.71; p < .001) remained at decreased risk for death as compared to patients with combined failure. CONCLUSION: Patients with distant-only and combined failures have a higher proportion of unfavorable clinical and biological features, and a lower survival than those with isolated local relapse.
Authors: Steve E Braunstein; Wendy B London; Susan G Kreissman; Judith G Villablanca; Andrew M Davidoff; Kenneth DeSantes; Robert P Castleberry; Kevin Murray; Lisa Diller; Katherine Matthay; Susan L Cohn; Barry Shulkin; Daniel von Allmen; Marguerite T Parisi; Collin Van Ryn; Julie R Park; Michael P La Quaglia; Daphne A Haas-Kogan Journal: Pediatr Blood Cancer Date: 2019-04-09 Impact factor: 3.167
Authors: Keith Holmes; Ulrike Pötschger; Andrew D J Pearson; Sabine Sarnacki; Giovanni Cecchetto; Javier Gomez-Chacon; Roly Squire; Enrique Freud; Adam Bysiek; Lucas E Matthyssens; Martin Metzelder; Tom Monclair; Jakob Stenman; Michal Rygl; Lars Rasmussen; Jean-Marc Joseph; Sabine Irtan; Stefano Avanzini; Jan Godzinski; Kristin Björnland; Martin Elliott; Roberto Luksch; Victoria Castel; Shifra Ash; Walentyna Balwierz; Geneviève Laureys; Ellen Ruud; Vassilios Papadakis; Josef Malis; Cormac Owens; Henrik Schroeder; Maja Beck-Popovic; Toby Trahair; Ana Forjaz de Lacerda; Peter F Ambros; Mark N Gaze; Kieran McHugh; Dominique Valteau-Couanet; Ruth Lydia Ladenstein Journal: J Clin Oncol Date: 2020-07-08 Impact factor: 44.544
Authors: Richard Li; Alexei Polishchuk; Steven DuBois; Randall Hawkins; Stephanie W Lee; Rochelle Bagatell; Suzanne Shusterman; Christine Hill-Kayser; Hasan Al-Sayegh; Lisa Diller; Daphne A Haas-Kogan; Katherine K Matthay; Wendy B London; Karen J Marcus Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-08 Impact factor: 7.038
Authors: F Berthold; B Hero; H Breu; H Christiansen; R Erttmann; A Gnekow; F Herrmann; T Klingebiel; F Lampert; S Müller-Weihrich; P Weinel Journal: Ann Oncol Date: 1996-02 Impact factor: 32.976
Authors: Daniel von Allmen; Andrew M Davidoff; Wendy B London; Collin Van Ryn; Daphne A Haas-Kogan; Susan G Kreissman; Geetika Khanna; Nancy Rosen; Julie R Park; Michael P La Quaglia Journal: J Clin Oncol Date: 2016-11-21 Impact factor: 44.544
Authors: Alexei L Polishchuk; Richard Li; Christine Hill-Kayser; Anthony Little; Randall A Hawkins; Jeffrey Hamilton; Michael Lau; Hung Chi Tran; Caron Strahlendorf; Richard S Lemons; Vivian Weinberg; Katherine K Matthay; Steven G DuBois; Karen J Marcus; Rochelle Bagatell; Daphne A Haas-Kogan Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-24 Impact factor: 7.038
Authors: Susan G Kreissman; Robert C Seeger; Katherine K Matthay; Wendy B London; Richard Sposto; Stephan A Grupp; Daphne A Haas-Kogan; Michael P Laquaglia; Alice L Yu; Lisa Diller; Allen Buxton; Julie R Park; Susan L Cohn; John M Maris; C Patrick Reynolds; Judith G Villablanca Journal: Lancet Oncol Date: 2013-07-25 Impact factor: 41.316
Authors: Daria Thompson; Kieuhoa T Vo; Wendy B London; Matthias Fischer; Peter F Ambros; Akira Nakagawara; Garrett M Brodeur; Katherine K Matthay; Steven G DuBois Journal: Cancer Date: 2015-12-28 Impact factor: 6.860
Authors: Kiana Kreitz; Angela Ernst; René Schmidt; Thorsten Simon; Matthias Fischer; Ruth Volland; Barbara Hero; Frank Berthold Journal: Cancer Med Date: 2019-10-20 Impact factor: 4.452